DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR TALAZOPARIB TOSYLATE
» See Plans and Pricing
All Clinical Trials for Talazoparib Tosylate
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02282345 | Neoadjuvant Talazoparib for Patients With a BRCA Deleterious Mutation | Recruiting | Medivation, Inc. | Phase 2 | 2015-04-01 | The goal of this clinical research study is to learn if talazoparib can help to control breast cancer that has a BRCA mutation (genetic change). The safety of talazoparib will also be studied. |
| NCT02282345 | Neoadjuvant Talazoparib for Patients With a BRCA Deleterious Mutation | Recruiting | M.D. Anderson Cancer Center | Phase 2 | 2015-04-01 | The goal of this clinical research study is to learn if talazoparib can help to control breast cancer that has a BRCA mutation (genetic change). The safety of talazoparib will also be studied. |
| NCT02286687 | Phase II Study of BMN 673 | Active, not recruiting | BioMarin Pharmaceutical | Phase 2 | 2014-12-01 | The goal of this clinical research study is to learn if talazoparib can help to control advanced cancer in patients who have a specific type of alteration. The safety of this drug will also be studied. |
| NCT02286687 | Phase II Study of BMN 673 | Active, not recruiting | M.D. Anderson Cancer Center | Phase 2 | 2014-12-01 | The goal of this clinical research study is to learn if talazoparib can help to control advanced cancer in patients who have a specific type of alteration. The safety of this drug will also be studied. |
| NCT02316834 | POSITION: A PilOt Study of InducTion PARP InhibitiON in Ovarian Cancer | Active, not recruiting | BioMarin Pharmaceutical | Phase 0 | 2015-06-01 | The goal of this clinical research study is to learn about the effects of BMN 673 on ovarian, Fallopian tube, and peritoneal cancer. Researchers want to find out if certain characteristics of the DNA (the genetic material in cells) affect how the disease responds to therapy with BMN 673 and if treatment with BMN 673 affects the genetic material in cancer cells. |
| NCT02316834 | POSITION: A PilOt Study of InducTion PARP InhibitiON in Ovarian Cancer | Active, not recruiting | M.D. Anderson Cancer Center | Phase 0 | 2015-06-01 | The goal of this clinical research study is to learn about the effects of BMN 673 on ovarian, Fallopian tube, and peritoneal cancer. Researchers want to find out if certain characteristics of the DNA (the genetic material in cells) affect how the disease responds to therapy with BMN 673 and if treatment with BMN 673 affects the genetic material in cancer cells. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Talazoparib Tosylate
Condition Name
Clinical Trial Locations for Talazoparib Tosylate
Trials by Country
Clinical Trial Progress for Talazoparib Tosylate
Clinical Trial Phase
Clinical Trial Status
Clinical Trial Sponsors for Talazoparib Tosylate
Sponsor Name
